This Dividend King With a 54-Year Dividend Streak Is Down 13% YTD. Time to Buy the Dip?

Core Viewpoint - Abbott Laboratories has experienced a 13% decline in stock price year-to-date, attracting attention from income-focused investors due to its strong dividend history and steady business expansion across various segments [1][2]. Group 1: Dividend Growth and Appeal - Abbott is recognized as a "Dividend King," having increased its dividends for 54 consecutive years, with a recent quarterly dividend increase of 6.8% to $0.63 per share [5]. - The company offers a forward dividend yield of approximately 2.2%, which is higher than the healthcare sector average of about 1.6%, making it attractive for passive income investors [1][4]. - Abbott's long-term commitment to returning cash to shareholders is evidenced by its 408th consecutive quarterly dividend since 1924, highlighting its financial stability [5]. Group 2: Financial Metrics and Sustainability - Abbott's payout ratio stands at about 40.3%, indicating that the dividend is well-supported by earnings, allowing for continued investment in innovation while maintaining dividend increases [6]. Group 3: Business Performance and Challenges - The company has faced challenges due to the normalization of pandemic-related diagnostic revenue, with a decline in Covid-19 testing demand impacting diagnostic sales growth [7]. - The nutrition segment has also been affected by higher manufacturing costs and price increases, which have slowed consumer demand and volume growth [7].